Latest Healthcare Research Reports

Tag: cinv market

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Outlook Reveals A CAGR Of 8% And A Market Value Of $4.56 Billion By 2030

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Outlook Reveals A CAGR Of 8% And A Market Value Of $4.56 Billion By 2030

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Revenue Outlook: What CAGR Is Expected Through 2030?

    The global market for managing chemotherapy-induced nausea and vomiting (CINV) has experienced substantial expansion. Projections indicate a progression from a valuation of $3.13 billion in 2025 to $3.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.0%. This upward trajectory during the historical period is underpinned by several key factors, including the heightened deployment of potent emetogenic chemotherapy regimens, a growing understanding of treatment-related adverse effects, enhanced accessibility to sophisticated antiemetic pharmaceuticals, the broadening scope of cancer treatment initiatives, and the refinement of clinical protocols for CINV control.

    The market for chemotherapy-induced nausea and vomiting (cinv) treatments is poised for significant expansion in the coming years, projected to reach $4.57 billion by 2030 with a compound annual growth rate (CAGR) of 8.0%. This anticipated growth is fueled by several key factors: escalating demand for advanced antiemetic medications, a greater integration of tailored antiemetic strategies into patient care, the augmentation of ambulatory chemotherapy administration, an intensified commitment to ensuring patients adhere to prescribed treatment plans, and continuous innovations in drug delivery systems designed for prolonged efficacy. Furthermore, prevailing trends shaping this market during the forecast period encompass a greater embrace of multi-drug antiemetic approaches, increased utilization of cinv medications with extended duration of action, a heightened concentration on treatment methodologies that prioritize the patient’s experience, broader implementation of proactive cinv management strategies, and a more pronounced focus on improving overall patient quality of life.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Momentum: Which Factors Are Influencing Demand?

    With cancer becoming more common, significant expansion is foreseen for the chemotherapy-induced nausea and vomiting (CINV) market. Cancer signifies aberrant cell proliferation and dissemination within the body. The escalating incidence of cancer globally is spurring greater investment in the creation of superior, specifically targeted anti-emetic interventions to mitigate CINV, an adverse and challenging consequence of cancer treatment. This intensified attention on managing CINV has facilitated progress in deciphering its fundamental processes and pioneering innovative treatments. For example, as reported by the American Cancer Society (ACS) in January 2023, the United States was projected to record 1.9 million new cancer diagnoses (averaging around 5,370 daily) and 609,820 cancer-related fatalities (approximately 1,670 daily) in 2023. Consequently, the rising tide of cancer cases will serve as a key impetus for the growth of the chemotherapy-induced nausea and vomiting (CINV) market.

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segment Analysis And Revenue Opportunities

    The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –

    1) By Form: Injectables, Oral, Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

    5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

    2) By Oral: Tablets, Capsules, Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends Reshaping Industry Growth

    Leading participants within the chemotherapy-induced nausea and vomiting (CINV) sector are actively pursuing novel product developments, including the introduction of fixed intravenous antiemetics, as a strategy to enhance their market standing. A fixed intravenous antiemetic signifies a pre-established dosage of medication delivered via an intravenous route intended to counteract or manage nausea and vomiting, frequently encountered in contexts such as chemotherapy treatment or following surgical procedures. Illustratively, in the month of January 2023, Glenmark Pharmaceuticals Limited, a pharmaceutical entity based in India involved in the production of pharmaceuticals, generic drugs, and over-the-counter items, launched AKYNZEO I.V. within India; this product marked the inaugural fixed intravenous antiemetic formulation specifically engineered for the prevention of chemotherapy-induced nausea and vomiting (CINV). This particular medicinal preparation integrates netupitant alongside palonosetron, addressing the occurrence of both immediate and prolonged periods of nausea and vomiting. It provides the advantage of a single administration, contributes to superior rates of complete symptom resolution, and ultimately elevates the well-being of individuals undergoing cancer therapy. Evidence from clinical investigations indicates its significant utility, especially for patients undergoing chemotherapy regimens characterized by a high emetogenic potential.

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Leading Players Shaping Industry Direction

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    Access The Complete Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Regional Analysis: Which Region Leads By Revenue?

    North Americawas the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis Through 2030 Focusing On Demand Trends And Growth Drivers

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis Through 2030 Focusing On Demand Trends And Growth Drivers

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Are The Forecasted Market Size Figures For The Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2026 And 2030?

    The market for chemotherapy-induced nausea and vomiting (cinv) has experienced substantial growth in recent years. This market is expected to expand from $3.13 billion in 2025 to $3.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be attributed to the increased application of highly emetogenic chemotherapy, a growing understanding of treatment side effects, the accessibility of advanced antiemetic drugs, the expansion of oncology treatment programs, and refined clinical guidelines for cinv management.

    The market size for chemotherapy-induced nausea and vomiting (cinv) is projected to experience robust expansion over the next few years. It is expected to reach $4.57 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.0%. This anticipated growth can be attributed to several factors, including the increasing demand for advanced antiemetics, the rising adoption of personalized antiemetic therapies, the expansion of outpatient chemotherapy services, a heightened focus on adherence to treatment protocols, and advancements in sustained-release formulations. Significant trends during the forecast period are expected to include the wider adoption of combination antiemetic regimens, increased utilization of long-acting cinv drugs, an evolving focus on patient-centric treatment approaches, the broadening of preventive cinv management protocols, and an enhanced emphasis on quality-of-life outcomes.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    What Key Growth Drivers Are Influencing The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    The expanding incidence of cancer is projected to fuel the chemotherapy-induced nausea and vomiting (CINV) market in the future. Cancer describes a condition where certain bodily cells proliferate uncontrollably and metastasize to other areas. With the ongoing rise in cancer diagnoses, there is an enhanced drive to create more potent and focused anti-emetic treatments to mitigate CINV, a challenging adverse effect of chemotherapy. This increased emphasis on CINV management has fostered progress in comprehending its fundamental mechanisms and in pioneering new therapies. For example, in January 2023, the American Cancer Society (ACS), a US-based volunteer health organization dedicated to eradicating cancer, estimated that the United States would see 1.9 million new cancer cases (around 5,370 cases daily) and 609,820 cancer deaths (approximately 1,670 deaths each day) in 2023. Consequently, the rising prevalence of cancer is set to propel the chemotherapy-induced nausea and vomiting (CINV) market.

    What Key Segment Areas Are Included In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Assessment?

    The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –

    1) By Form: Injectables, Oral, Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

    5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

    2) By Oral: Tablets, Capsules, Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

    Which Trends Are Affecting The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Framework?

    Key entities active within the chemotherapy-induced nausea and vomiting (CINV) market are focusing on novel product innovations, including fixed intravenous antiemetics, to secure a competitive edge. This type of antiemetic involves a pre-set quantity of medicine delivered intravenously to manage or avert nausea and vomiting, frequently employed in contexts like chemotherapy or following surgical procedures. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based producer of pharmaceuticals, generics, and over-the-counter (OTC) products, launched AKYNZEO I.V. in India, marking it as the initial fixed intravenous antiemetic combination specifically formulated to prevent chemotherapy-induced nausea and vomiting (CINV). The product integrates netupitant and palonosetron, effectively addressing both the acute and delayed manifestations of nausea and vomiting. It provides the benefit of single-dose administration, contributes to higher complete response rates, and elevates the quality of life for individuals battling cancer. Clinical research has indicated its distinct advantage for patients receiving highly emetogenic chemotherapy.

    Which Companies Are Influencing The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    Access The Complete Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    Which Region Leads The Chemotherapy-Induced Nausea and Vomiting (CINV) Market By Size?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

    Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026, By The Business Research Company

    Myeloproliferative Disorders Drugs Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

    Chemotherapy Induced Anemia Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

    Chemotherapy Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • CINV Market Forecast (2026–2030): Expansion Trends

    CINV Market Forecast (2026–2030): Expansion Trends

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Is The Market Size Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Expected To Change From 2026 To 2030?

    The market size for chemotherapy-induced nausea and vomiting (cinv) has experienced strong growth in recent years. It is projected to expand from $3.13 billion in 2025 to $3.35 billion in 2026, at a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be attributed to the increasing use of highly emetogenic chemotherapy, a rising awareness of treatment side effects, the availability of advanced antiemetic drugs, the expansion of oncology treatment programs, and improved clinical guidelines for cinv management.

    The chemotherapy-induced nausea and vomiting (CINV) market is projected to witness substantial growth over the next few years. It is forecast to grow to $4.57 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.0%. This anticipated expansion during the forecast period is driven by increasing demand for next-generation antiemetics, the rising adoption of personalized antiemetic therapy, the expansion of outpatient chemotherapy services, a growing emphasis on adherence to treatment protocols, and advancements in sustained-release formulations. Significant trends expected in the forecast period include a greater adoption of combination antiemetic regimens, an increased use of long-acting CINV drugs, a strengthening focus on patient-centric treatment approaches, the broadening of preventive CINV management protocols, and an enhanced emphasis on quality-of-life outcomes.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    What Key Factors Are Affecting The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Demand?

    The rising occurrence of cancer is projected to stimulate the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the future. Cancer refers to a condition where certain body cells grow uncontrollably and disseminate to other parts of the body. With the continuous increase in cancer incidents, there is a stronger motivation to create more potent and specific anti-emetic solutions to mitigate CINV, a difficult side effect of chemotherapy. This increased emphasis on managing CINV has resulted in progress in understanding its fundamental processes and creating new treatments. For example, in January 2023, the American Cancer Society (ACS), a US-based volunteer health organization dedicated to eradicating cancer, projected that in the United States, there would be 1.9 million new cancer cases (around 5,370 cases daily) and 609,820 cancer deaths (approximately 1,670 deaths daily) in 2023. Consequently, the growing incidence of cancer will fuel the chemotherapy-induced nausea and vomiting (CINV) market.

    Which Segment Types Are Examined In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segment Study?

    The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –

    1) By Form: Injectables, Oral, Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

    5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

    2) By Oral: Tablets, Capsules, Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

    What Trends Are Influencing Changes In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Major companies in the chemotherapy-induced nausea and vomiting (CINV) market are focusing on new product innovations, such as fixed intravenous antiemetics, to achieve a competitive advantage. A fixed intravenous antiemetic is a specific quantity of medication given through an IV to prevent or treat nausea and vomiting, often used in chemotherapy or after surgery. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based producer of pharmaceuticals, generics, and over-the-counter (OTC) items, released AKYNZEO I.V. in India. This was the first fixed intravenous antiemetic combination developed to prevent chemotherapy-induced nausea and vomiting (CINV). The product combines netupitant and palonosetron, targeting both the early and later phases of nausea and vomiting. It offers convenience with a single dose, leads to improved complete response rates, and enhances the quality of life for cancer patients. Clinical studies demonstrate its particular usefulness for patients undergoing highly emetogenic chemotherapy.

    Which Players Are Part Of The Competitive Landscape Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    Get The Full Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    Where Is The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Primarily Concentrated By Region?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026, By The Business Research Company

    Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

    Chemotherapy Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

    Chemotherapy Induced Anemia Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Market Developments and Growth Opportunities Across 2026–2030

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Developments and Growth Opportunities Across 2026–2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Will The Market Size Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Evolve From 2026 To 2030?

    The market for chemotherapy-induced nausea and vomiting (cinv) has experienced robust growth over recent years. This market is projected to expand from $3.13 billion in 2025 to $3.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be ascribed to several factors, including the increasing application of highly emetogenic chemotherapy, greater recognition of treatment side effects, the introduction of advanced antiemetic medications, the broadening of oncology treatment initiatives, and enhanced clinical directives for managing cinv.

    The market for chemotherapy-induced nausea and vomiting (cinv) is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $4.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this anticipated growth include a heightened demand for advanced antiemetics, the increasing embrace of tailored antiemetic treatments, the broadening of outpatient chemotherapy provisions, an intensified focus on complying with treatment guidelines, and developments in formulations designed for sustained release. Key developments expected during this period encompass a greater acceptance of combined antiemetic strategies, increased utilization of prolonged-release cinv medications, an evolving emphasis on care models centered around patients, the proliferation of preventive cinv management strategies, and a stronger focus on improving patients’ quality of life.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    What Major Drivers Are Influencing Demand In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    The expanding incidence of cancer is projected to boost the chemotherapy-induced nausea and vomiting (CINV) market in the coming period. Cancer refers to a condition where certain bodily cells proliferate uncontrollably and metastasize to other areas. With the ongoing rise in cancer diagnoses, there’s a stronger impetus to create more potent and focused anti-emetic therapies to mitigate CINV, a severe consequence of chemotherapy. This sharpened emphasis on managing CINV has resulted in progress in comprehending its fundamental mechanisms and in devising new treatments. For example, in January 2023, the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, reported that in the United States, an estimated 1.9 million new cancer cases (roughly 5,370 cases daily) and 609,820 cancer deaths (around 1,670 deaths daily) are expected in 2023. Consequently, the growing occurrence of cancer will propel the chemotherapy-induced nausea and vomiting (CINV) market.

    Which Segment Areas Are Covered In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis?

    The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –

    1) By Form: Injectables, Oral, Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

    5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

    2) By Oral: Tablets, Capsules, Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

    Which Trends Are Influencing The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Leading companies active in the chemotherapy-induced nausea and vomiting (CINV) market are developing innovative products, such as fixed intravenous antiemetics, to achieve a competitive edge. A fixed intravenous antiemetic denotes a specific dose of medicine delivered via an IV to avert or treat nausea and vomiting, frequently utilized during chemotherapy or after surgery. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based producer of pharmaceuticals, generics, and over-the-counter (OTC) items, released AKYNZEO I.V. in India. This was the first fixed intravenous antiemetic combination crafted to prevent chemotherapy-induced nausea and vomiting (CINV). The product merges netupitant and palonosetron, addressing both the immediate and delayed phases of nausea and vomiting. It offers the benefit of single-dose convenience, leads to improved complete response rates, and enhances the quality of life for cancer patients. Clinical investigations demonstrate its notable effectiveness for patients receiving highly emetogenic chemotherapy.

    Which Global Companies Are Actively Competing In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    Read the full chemotherapy-induced nausea and vomiting (cinv) market report here:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    Which Region Shows The Strongest Potential For Future Growth In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Chemotherapy-Induced Nausea and Vomiting (CINV) Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

    Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026, By The Business Research Company

    Myeloproliferative Disorders Drugs Global Market Report

    https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

    Chemotherapy Induced Anemia Global Market Report

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

    Chemotherapy Global Market Report

    https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026–2030: Forecasting Business Opportunities Ahead

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026–2030: Forecasting Business Opportunities Ahead

    Uncover key drivers, emerging technologies, and competitive movements shaping the chemotherapy-induced nausea and vomiting (cinv) market from 2026–2035 with trusted insights from The Business Research Company

    What size range is anticipated for the Chemotherapy-Induced Nausea and Vomiting (CINV) Market from 2026 to 2030?

    The chemotherapy-induced nausea and vomiting (cinv) market size has seen substantial growth in recent years. It is anticipated to expand from $3.13 billion in 2025 to $3.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. The expansion observed historically can be ascribed to factors such as the increasing utilization of highly emetogenic chemotherapy, a growing understanding of treatment-related side effects, the emergence of advanced antiemetic drugs, the broadening of oncology treatment initiatives, and improvements in clinical guidelines for cinv management.

    The market for chemotherapy-induced nausea and vomiting (cinv) is projected to experience robust expansion in the coming years. This market is anticipated to reach $4.57 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. Factors driving this growth during the forecast period include a surging demand for innovative antiemetics, the increasing embrace of tailored antiemetic treatments, the broadening of outpatient chemotherapy provisions, an intensified emphasis on adherence to prescribed treatment regimens, and improvements in sustained-release drug formulations. Key trends projected for the forecast period encompass a greater uptake of combined antiemetic approaches, an increased reliance on extended-release CINV medications, a heightened focus on care models centered around patients, the development of more extensive preventive CINV management guidelines, and a stronger accent on improving patients’ quality of life.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    What Drivers Are Affecting Demand In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    The rising incidence of cancer is projected to fuel the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the future. Cancer occurs when certain cells in the body multiply without control and disseminate to different parts of the body. With the ongoing increase in cancer diagnoses, there’s an amplified motivation to create more potent and specific anti-emetic therapies to mitigate CINV, a troubling consequence of chemotherapy. This intensified attention on managing CINV has resulted in progress in deciphering its fundamental processes and devising new treatments. For instance, in January 2023, the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, projected that the United States would experience 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) during 2023. Consequently, the growing occurrence of cancer will propel the chemotherapy-induced nausea and vomiting (CINV) market.

    Which Segments Are Gaining Traction In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –

    1) By Form: Injectables, Oral, Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

    5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

    2) By Oral: Tablets, Capsules, Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

    What Industry Trends Are Transforming The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Leading companies in the chemotherapy-induced nausea and vomiting (CINV) market are pursuing novel product developments, such as fixed intravenous antiemetics, to gain a competitive edge. This form of antiemetic involves a predefined drug dose administered intravenously to prevent or alleviate nausea and vomiting, commonly employed in chemotherapy or post-surgical recovery. For instance, in January 2023, Glenmark Pharmaceuticals Limited, an India-based manufacturer of pharmaceuticals, generics, and over-the-counter products, introduced AKYNZEO I.V. in India. This product stands as the first fixed intravenous antiemetic combination specifically designed to prevent chemotherapy-induced nausea and vomiting (CINV). It brings together netupitant and palonosetron to tackle both immediate and prolonged phases of nausea and vomiting. The product provides the convenience of a single dose, better complete response rates, and an improved quality of life for cancer patients. Clinical research demonstrates its particular efficacy for patients undergoing highly emetogenic chemotherapy.

    Who Are The Prominent Global Companies Shaping The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Landscape?

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    Which Region Currently Holds The Largest Share Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Chemotherapy-Induced Nausea and Vomiting (CINV) Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

    Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026, By The Business Research Company

    Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

    Chemotherapy Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

    Chemotherapy Induced Anemia Market Report 2026

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Market Emerging Trends and Growth Drivers Through 2029 | Reach USD $4.19 Billion

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Emerging Trends and Growth Drivers Through 2029 | Reach USD $4.19 Billion

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Is The Present And Forecasted Size Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    In recent times, the market size for chemotherapy-induced nausea and vomiting (cinv) has shown significant growth. It is predicted to expand from $2.92 billion in 2024 to $3.13 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.4%. The historic growth phase can be attributed to factors such as an increase in the use of chemotherapy, the enhancement of antiemetic agents, clinical guidelines, and patient advocacy.

    The market size of chemotherapy-induced nausea and vomiting (CINV) is predicted to witness substantial expansion in the upcoming years, reaching $4.19 billion in 2029 with a compound annual growth rate (CAGR) of 7.5%. This growth in the forecast era can largely be attributed to factors such as customised medicine, advancements in antiemetic drugs, telemedicine, remote patient monitoring, and health fairness initiatives. Notable trends anticipated within the forecast timeframe involve combination antiemetic treatments, supportive care provisions, virtual health technology, and survivorship care.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    What Drivers Are Accelerating Expansion Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    The continuous rise in cancer occurrences is predicted to stimulate the growth of the market for chemotherapy-induced nausea and vomiting (CINV). Cancer is a condition where body cells multiply uncontrollably and spread throughout the body. As the number of cancer cases escalates, there’s a heightened enthusiasm to formulate more precise and efficacious anti-emetic therapies to mitigate CINV, an unpleasant aftermath of chemotherapy. This increased emphasis on managing CINV has resulted in progress in comprehending its core causes and creating innovative treatments. For instance, in January 2023, as per the American Cancer Society (ACS), a volunteer health organization based in the US with a mission to eliminate cancer, roughly 5,370 new cancer cases and about 1,670 cancer-related deaths are expected daily, totaling 1.9 million and 609,820 respectively for the year in the United States. Consequently, the intensifying occurrence of cancer is anticipated to fuel the market for chemotherapy-induced nausea and vomiting (CINV).

    What Are The Primary Segmentation Parameters In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    The chemotherapy-induced nausea and vomiting (cinv)market covered in this report is segmented –

    1) By Form: Injectables; Oral; Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores

    5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections

    2) By Oral: Tablets; Capsules; Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches

    How Are Industry Trends Steering The Expansion Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Key players in the market of chemotherapy-induced nausea and vomiting (CINV) are striving to gain a competitive edge through the invention of new products like the fixed intravenous antiemetic. This refers to a set dosage of medication, administered via an IV, that is used to prevent or manage nausea and vomiting typically occurring after chemotherapy or surgery. A case in point is Glenmark Pharmaceuticals Limited, an Indian pharmaceuticals, generics, and over-the-counter (OTC) products manufacturer, which launched AKYNZEO I.V., the first-ever fixed intravenous antiemetic combination, in India in January 2023. This product, a blend of netupitant and palonosetron, is aimed at managing both the initial and delayed stages of nausea and vomiting. It allows for convenience with a single dose, better complete response rates, and an improved quality of life for cancer patients, showing significant benefits for patients undergoing highly emetogenic chemotherapy, as per clinical research.

    Which Players Are Shaping The Competitive Landscape Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    What Are The Emerging Regional Trends Driving The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

    Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2025, By The Business Research Company

    Viral Vectors And Plasmid Dna Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

    Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

    Chemotherapy Induced Anemia Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forecast 2025–2034: Where Businesses Should Invest Next

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forecast 2025–2034: Where Businesses Should Invest Next

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Are The Forecasted Market Size Estimates For The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Between 2025 And 2029?

    The market size for chemotherapy-induced nausea and vomiting (cinv) has experienced robust growth in recent years. It is projected to expand from $2.92 billion in 2024 to $3.13 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.4%. The expansion observed in the historical period can be attributed to an increase in chemotherapy use, the advent of improved antiemetic agents, the establishment of clinical guidelines, and strengthened patient advocacy.

    The market size for chemotherapy-induced nausea and vomiting (CINV) is anticipated to experience robust expansion over the coming years. It is projected to reach $4.19 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this growth during the projected period include personalized medicine, continuous advancements in antiemetic agents, the rise of telehealth and remote monitoring, and various health equity initiatives. Key trends foreseen in this forecast period encompass the adoption of combination antiemetic therapies, a focus on supportive care services, the integration of digital health tools, and enhanced survivorship care.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    Which Major Market Drivers Are Shaping The Future Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    The rising incidence of cancer is projected to fuel the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the coming years. Cancer is characterized by the uncontrolled proliferation and dissemination of certain cells throughout the body. The persistent increase in cancer diagnoses provides a stronger impetus for creating more potent and focused anti-emetic therapies to mitigate CINV, a troubling consequence of chemotherapy. This intensified emphasis on managing CINV has resulted in progress in deciphering its fundamental mechanisms and in pioneering new treatments. For example, the American Cancer Society (ACS), a US-based volunteer health organization dedicated to eradicating cancer, reported in January 2023 that the United States is expected to see 1.9 million new cancer cases (roughly 5,370 cases daily) and 609,820 cancer deaths (approximately 1,670 deaths per day) in 2023. Consequently, the expanding occurrence of cancer will propel the chemotherapy-induced nausea and vomiting (CINV) market.

    What Are The Major Segment Types Covered In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    The chemotherapy-induced nausea and vomiting (cinv)market covered in this report is segmented –

    1) By Form: Injectables; Oral; Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores

    5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections

    2) By Oral: Tablets; Capsules; Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches

    Which Trends Are Impacting The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Leading companies in the chemotherapy-induced nausea and vomiting (CINV) market are pursuing new product innovations, such as fixed intravenous antiemetics, to gain a competitive advantage. A fixed intravenous antiemetic is defined as a specific dose of medication delivered via IV to prevent or treat nausea and vomiting, frequently employed in chemotherapy or post-surgical environments. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based producer of pharmaceuticals, generics, and over-the-counter products, launched AKYNZEO I.V. in India. This product represents the inaugural fixed intravenous antiemetic combination created to avert chemotherapy-induced nausea and vomiting (CINV). It combines netupitant and palonosetron, effectively targeting both the acute and delayed stages of nausea and vomiting. The solution offers the benefit of single-dose administration, yielding improved complete response rates and a better quality of life for cancer patients. Furthermore, clinical studies have demonstrated its specific utility for patients receiving highly emetogenic chemotherapy.

    Which Global Market Leaders Are Shaping The Future Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Sector?

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    What Are The Regional Market Dynamics Impacting The Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Request A Customized Version Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

    Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2025, By The Business Research Company

    Viral Vectors And Plasmid Dna Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

    Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

    Chemotherapy Induced Anemia Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • $4.19 Billion Forecast for Chemotherapy-Induced Nausea and Vomiting (CINV) Market by 2029, Backed by Demand and Innovation

    $4.19 Billion Forecast for Chemotherapy-Induced Nausea and Vomiting (CINV) Market by 2029, Backed by Demand and Innovation

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Evolved From 2024 To 2025, And What’s Ahead?

    The market size for chemotherapy-induced nausea and vomiting (CINV) has experienced substantial expansion in the past years. The market value is expected to rise from $2.92 billion in 2024 to $3.13 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. The surge in the historic timeframe can be attributed to an increase in chemotherapy usage, heightened antiemetic agents, clinical guideline advancements, and patient advocacy.

    The market for chemotherapy-induced nausea and vomiting (CINV) is projected to experience significant growth in the coming years, reaching $4.19 billion in 2029 with a compound annual growth rate (CAGR) of 7.5%. The expected growth within the forecast period can be connected to the development of personalized medicine, improvements in antiemetic treatments, the rise in telehealth and remote monitoring, as well as health equity initiatives. The forecast period also signals key trends such as the increased use of combination antiemetic therapies, a rise in supportive care services, wider use of digital health tools, and an emphasis on survivorship care.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    What Are the Core Growth Drivers Propelling the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Forward?

    The rise in cancer occurrence is predicted to fuel the expansion of the chemotherapy-induced nausea and vomiting (CINV) market. Cancer develops when certain cells in the body grow out of control and invade other areas of the body. As the number of cancer patients increases, so does the urgency to create more targeted and efficient anti-emetic treatments to alleviate CINV, an unsettling side effect of chemotherapy. This intensified interest in managing CINV has led to progress in understanding its basic causes and the development of new treatments. For example, the American Cancer Society (ACS), a US-based volunteer health organization dedicated to eliminating cancer, anticipates there will be 1.9 million new cancer cases (around 5,370 cases per day) and 609,820 cancer-related deaths (approximately 1,670 deaths per day) in the United States in January 2023. As such, the rising prevalence of cancer is set to boost the chemotherapy-induced nausea and vomiting (CINV) market.

    What Segment Types Define the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Structure?

    The chemotherapy-induced nausea and vomiting (cinv)market covered in this report is segmented –

    1) By Form: Injectables; Oral; Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores

    5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections

    2) By Oral: Tablets; Capsules; Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

    Which Geographic Areas Hold the Strongest Growth Potential in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Which Emerging Trends that Are Influencing theChemotherapy-Induced Nausea and Vomiting (CINV) Industry Evolution?

    Leading firms in the chemotherapy-induced nausea and vomiting (CINV) sector have been focusing on new innovative products, like fixed intravenous antiemetic, to strengthen their market position. Such fixed intravenous antiemetics refer to a pre-determined medication dosage given through IV to manage nausea and vomiting, typically in post-surgery and chemotherapy situations. For instance, in January 2023, Glenmark Pharmaceuticals Limited, an Indian pharmaceutical, generics, and over-the-counter (OTC) goods manufacturer, brought the first fixed intravenous antiemetic combination, AKYNZEO I.V., to India. This product is specifically designed to combat CINV and includes a blend of netupitant and palonosetron, aiming to handle both the immediate and delayed phases of nausea and vomiting. It provides convenience of a single dose, improved total response rates and enhances the quality of life for cancer patients. According to clinical research, it has shown to be particularly advantageous for those undergoing highly emetogenic chemotherapy.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    What Is the Definition of the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Chemotherapy-induced nausea and vomiting (CINV) is a condition that causes nausea and vomiting sensation, which can develop due to chemotherapy treatment. It is a prevalent side-effect affecting many cancer patients, affecting their quality of life and treatment results. CINV can be managed and treated through medications and lifestyle changes.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Industry Insights 2025 – Market Forecast for Executives and Planners

    Chemotherapy-Induced Nausea and Vomiting (CINV) Industry Insights 2025 – Market Forecast for Executives and Planners

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Changed, over the years?

    There has been a significant increase in the market size of chemotherapy-induced nausea and vomiting (CINV) in the past years. Anticipated growth from $2.92 billion in 2024 to $3.15 billion in 2025, translating to a compound annual growth rate (CAGR) of 7.9%, is predicted. Factors such as the escalating use of chemotherapy, enhanced antiemetic agents, developed clinical guidelines, and patient advocacy are credited for the growth witnessed in the historical period.

    How Much Will the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Be Worth in 2029?

    The market size for chemotherapy-induced nausea and vomiting (CINV) is anticipated to witness significant growth in the upcoming years. The CINV market size is projected to reach $4.2 billion in 2029, with a compound annual growth rate (CAGR) of 7.5%. This projected growth in the forecast period is due to factors such as personalized medicine, the progress in antiemetic agents, telehealth and remote monitoring, and health equity initiatives. Key trends expected during the forecast period encompass combined antiemetic therapies, supportive care services, digital health instruments, and survivorship care.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    Which is the Largest Company in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    What Are the Main Market Drivers in the Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?

    As cancer rates continue to rise, it is anticipated that the chemotherapy-induced nausea and vomiting (CINV) market will likewise experience growth. Cancer occurs when cells develop without restraint and spread throughout the body. The rising occurrence of cancer has prompted a stronger drive towards devising more potent and specific anti-emetic therapies to manage CINV, a bothersome by-product of chemotherapy treatment. The intensified attention towards managing CINV has contributed to progress in comprehending its causative biological processes and crafting new treatments. The American Cancer Society, a volunteer health group devoted to eliminating cancer in the U.S, reported that by January 2023, there would approximately be 1.9 million new cancer cases and 609,820 cancer-related deaths. Consequently, the mounting prevalence of cancer is expected to stimulate the chemotherapy-induced nausea and vomiting (CINV) market.

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Driver: Regulatory Initiatives Contribute to Market Growth

     

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

    How Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segments Structured?

    The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –

    1) By Form: Injectables, Oral, Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

    5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

    2) By Oral: Tablets, Capsules, Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

    What Strategic Trends Are Transforming the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    In the chemotherapy-induced nausea and vomiting (CINV) industry, key players are adopting strategies such as launching new products with advanced features like fixed intravenous antiemetic to hold a competitive edge. This term signifies a medication that is given through an IV at a prespecified dose to alleviate or prevent nausea and vomiting, a common occurrence post surgery or during chemotherapy. For instance, Glenmark Pharmaceuticals Limited, a producer of pharmaceuticals, generic drugs, and consumer health products based in India, rolled out AKYNZEO I.V. in India in January 2023, marking the first appearance of a fixed intravenous antiemetic combo produced for CINV prevention. The product blends netupitant and palonosetron, offering a treatment for both immediate and delayed instances of nausea and vomiting. It offers the convenience of a single dose, enhancing complete response rates and improving quality of life for individuals with cancer. Clinical research suggests its efficacy is especially noteworthy for patients undergoing highly emetogenic chemotherapy.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    Which Global Regions Offer the Highest Growth in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031

    This Report Delivers Insight On:

    1. How big is the chemotherapy-induced nausea and vomiting (cinv) market, and how is it changing globally?

    2. Who are the major companies in the chemotherapy-induced nausea and vomiting (cinv) market, and how are they performing?

    3. What are the key opportunities and risks in the chemotherapy-induced nausea and vomiting (cinv) market right now?

    4. Which products or customer segments are growing the most in the chemotherapy-induced nausea and vomiting (cinv) market?

    5. What factors are helping or slowing down the growth of the chemotherapy-induced nausea and vomiting (cinv) market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Chemotherapy-Induced Nausea and Vomiting (CINV) Industry Insights 2025 – Market Forecast for Executives and Planners

    Chemotherapy-Induced Nausea and Vomiting (CINV) Industry Insights 2025 – Market Forecast for Executives and Planners

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Changed, over the years?

    There has been a significant increase in the market size of chemotherapy-induced nausea and vomiting (CINV) in the past years. Anticipated growth from $2.92 billion in 2024 to $3.15 billion in 2025, translating to a compound annual growth rate (CAGR) of 7.9%, is predicted. Factors such as the escalating use of chemotherapy, enhanced antiemetic agents, developed clinical guidelines, and patient advocacy are credited for the growth witnessed in the historical period.

    How Much Will the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Be Worth in 2029?

    The market size for chemotherapy-induced nausea and vomiting (CINV) is anticipated to witness significant growth in the upcoming years. The CINV market size is projected to reach $4.2 billion in 2029, with a compound annual growth rate (CAGR) of 7.5%. This projected growth in the forecast period is due to factors such as personalized medicine, the progress in antiemetic agents, telehealth and remote monitoring, and health equity initiatives. Key trends expected during the forecast period encompass combined antiemetic therapies, supportive care services, digital health instruments, and survivorship care.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp

    Which is the Largest Company in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

    What Are the Main Market Drivers in the Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?

    As cancer rates continue to rise, it is anticipated that the chemotherapy-induced nausea and vomiting (CINV) market will likewise experience growth. Cancer occurs when cells develop without restraint and spread throughout the body. The rising occurrence of cancer has prompted a stronger drive towards devising more potent and specific anti-emetic therapies to manage CINV, a bothersome by-product of chemotherapy treatment. The intensified attention towards managing CINV has contributed to progress in comprehending its causative biological processes and crafting new treatments. The American Cancer Society, a volunteer health group devoted to eliminating cancer in the U.S, reported that by January 2023, there would approximately be 1.9 million new cancer cases and 609,820 cancer-related deaths. Consequently, the mounting prevalence of cancer is expected to stimulate the chemotherapy-induced nausea and vomiting (CINV) market.

    Chemotherapy-Induced Nausea and Vomiting (CINV) Market Driver: Regulatory Initiatives Contribute to Market Growth

     

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp

    How Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segments Structured?

    The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented –

    1) By Form: Injectables, Oral, Transdermal Patches

    2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class

    3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)

    4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores

    5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications

    Subsegments:

    1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections

    2) By Oral: Tablets, Capsules, Liquid Formulations

    3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches

    What Strategic Trends Are Transforming the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    In the chemotherapy-induced nausea and vomiting (CINV) industry, key players are adopting strategies such as launching new products with advanced features like fixed intravenous antiemetic to hold a competitive edge. This term signifies a medication that is given through an IV at a prespecified dose to alleviate or prevent nausea and vomiting, a common occurrence post surgery or during chemotherapy. For instance, Glenmark Pharmaceuticals Limited, a producer of pharmaceuticals, generic drugs, and consumer health products based in India, rolled out AKYNZEO I.V. in India in January 2023, marking the first appearance of a fixed intravenous antiemetic combo produced for CINV prevention. The product blends netupitant and palonosetron, offering a treatment for both immediate and delayed instances of nausea and vomiting. It offers the convenience of a single dose, enhancing complete response rates and improving quality of life for individuals with cancer. Clinical research suggests its efficacy is especially noteworthy for patients undergoing highly emetogenic chemotherapy.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report

    Which Global Regions Offer the Highest Growth in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?

    North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031

    This Report Delivers Insight On:

    1. How big is the chemotherapy-induced nausea and vomiting (cinv) market, and how is it changing globally?

    2. Who are the major companies in the chemotherapy-induced nausea and vomiting (cinv) market, and how are they performing?

    3. What are the key opportunities and risks in the chemotherapy-induced nausea and vomiting (cinv) market right now?

    4. Which products or customer segments are growing the most in the chemotherapy-induced nausea and vomiting (cinv) market?

    5. What factors are helping or slowing down the growth of the chemotherapy-induced nausea and vomiting (cinv) market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model